KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gains from Investment Securities (2016 - 2026)

Alnylam Pharmaceuticals filings provide 16 years of Gains from Investment Securities readings, the most recent being $2.4 million for Q1 2026.

  • Quarterly Gains from Investment Securities fell 75.89% to $2.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Mar 2026, down 25.18% year-over-year, with the annual reading at $21.2 million for FY2025, 127.68% up from the prior year.
  • Gains from Investment Securities hit $2.4 million in Q1 2026 for Alnylam Pharmaceuticals, down from $8.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.8 million in Q1 2025 and bottomed at -$7.8 million in Q3 2024.
  • Average Gains from Investment Securities over 5 years is $2.6 million, with a median of $3.1 million recorded in 2025.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 3130.3% in 2022 before it plummeted 275.6% in 2024.
  • Alnylam Pharmaceuticals' Gains from Investment Securities stood at -$4.1 million in 2022, then skyrocketed by 54.01% to -$1.9 million in 2023, then soared by 598.34% to $9.3 million in 2024, then dropped by 5.3% to $8.8 million in 2025, then tumbled by 73.13% to $2.4 million in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Gains from Investment Securities are $2.4 million (Q1 2026), $8.8 million (Q4 2025), and $3.8 million (Q3 2025).